204 related articles for article (PubMed ID: 17032931)
1. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism.
Burleigh E; Wang C; Foster D; Heller S; Dunn D; Safavi K; Griffin B; Smith J
Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S23-9. PubMed ID: 17032931
[TBL] [Abstract][Full Text] [Related]
2. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
4. Hospital-based costs associated with venous thromboembolism treatment regimens.
Merli G; Ferrufino C; Lin J; Hussein M; Battleman D
J Thromb Haemost; 2008 Jul; 6(7):1077-86. PubMed ID: 18445118
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
6. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
7. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.
McGarry LJ; Thompson D
Clin Ther; 2004 Mar; 26(3):419-30. PubMed ID: 15110135
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
Wilbur K; Lynd LD; Sadatsafavi M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
Offord R; Lloyd AC; Anderson P; Bearne A
Pharm World Sci; 2004 Aug; 26(4):214-20. PubMed ID: 15446778
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
[TBL] [Abstract][Full Text] [Related]
14. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
[TBL] [Abstract][Full Text] [Related]
15. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.
Turpie AG; Norris TM
Thromb Haemost; 2004 Jul; 92(1):3-12. PubMed ID: 15213839
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.
McGarry LJ; Stokes ME; Thompson D
Thromb J; 2006 Sep; 4():17. PubMed ID: 17005045
[TBL] [Abstract][Full Text] [Related]
17. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
19. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients.
Dobesh PP; Stacy ZA
J Manag Care Pharm; 2005; 11(9):755-62. PubMed ID: 16300419
[TBL] [Abstract][Full Text] [Related]
20. [Two models of thromboprophylaxis in acutely ill medical inpatients].
Luba M; Firek A; Kochanowski Z
Pol Arch Med Wewn; 2007 Apr; 117(4):31-7. PubMed ID: 17722473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
